Ultragenyx Pharmaceutical Inc ASGCT DTX301 and DTX401 Data Updates Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the Ultragenyx 2020 ASGCT Investor Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions) I would now like to hand the conference over to your speaker today, Danielle Keatley. Thank you. Please go ahead, ma'am.
Thank you, and good morning. Welcome to the Ultragenyx Conference Call to discuss the data presented at the American Society of Gene & Cell Therapy virtual meeting to speak. We issued press releases earlier detailing the data results from the DTX301 and DTX401 studies, and slides to accompany this call can be found on our website at ultragenyx.com.
With me today is Emil Kakkis, Chief Executive Officer and President of Ultragenyx. I'd like to remind investors that this call will include forward-looking statements, including those related to management's outlook or predications of future results. These
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |